Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database.
Healthcare resource utilization
Oral corticosteroids
Real-world data
Tofacitinib
Ulcerative colitis
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
14
02
2023
accepted:
26
07
2023
medline:
25
9
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
ppublish
Résumé
Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). To evaluate real-world data in US patients with UC receiving tofacitinib. Characteristics and outcomes of patients with UC initiating tofacitinib between 2018 and 2019 were assessed using data from the IBM® MarketScan® claims database. The index date was the first tofacitinib claim; pre- and post-index periods were 12 months. Outcomes included tofacitinib adherence/persistence, oral corticosteroid (OCS) use, and healthcare resource utilization (HCRU) and costs. Of 276 patients with UC who initiated tofacitinib, 68 (24.6%) were bio-naïve, and 208 (75.4%) bio-experienced. At month 12, overall median tofacitinib adherence (proportion of days covered) was 0.82 (mean 0.68); 43.8% of patients discontinued tofacitinib (90-day gap). Of patients receiving OCS during the post-index 16-week tapering period, 40.4% discontinued OCS up to 12 months post-index. OCS use decreased in patients continuing tofacitinib versus those discontinuing tofacitinib (29.7% vs 59.5%, respectively). Reductions in all-cause and UC-related outpatient visits were observed for bio-naïve (- 1.34 and - 0.88, respectively) and bio-experienced (- 4.72 and - 5.16, respectively) patients, post-index. Decreased UC-related costs per year were observed for bio-experienced patients (difference in post-index vs pre-index, - US$12,448; driven by changes in pharmacy costs), but not for bio-naïve patients (US$47,152). In this real-world analysis in a mostly bio-experienced population, the majority of US patients with UC initiating tofacitinib remained on therapy at 12 months, and OCS use was reduced with tofacitinib treatment. HCRU (all patients) and UC-related costs were reduced in bio-experienced patients. The majority of patients with ulcerative colitis starting tofacitinib in this real-world study continued therapy at 12 months; there was a reduction in the use of steroids, and a decrease in healthcare resournce utilization and costs.
Sections du résumé
BACKGROUND
Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC).
AIMS
To evaluate real-world data in US patients with UC receiving tofacitinib.
METHODS
Characteristics and outcomes of patients with UC initiating tofacitinib between 2018 and 2019 were assessed using data from the IBM® MarketScan® claims database. The index date was the first tofacitinib claim; pre- and post-index periods were 12 months. Outcomes included tofacitinib adherence/persistence, oral corticosteroid (OCS) use, and healthcare resource utilization (HCRU) and costs.
RESULTS
Of 276 patients with UC who initiated tofacitinib, 68 (24.6%) were bio-naïve, and 208 (75.4%) bio-experienced. At month 12, overall median tofacitinib adherence (proportion of days covered) was 0.82 (mean 0.68); 43.8% of patients discontinued tofacitinib (90-day gap). Of patients receiving OCS during the post-index 16-week tapering period, 40.4% discontinued OCS up to 12 months post-index. OCS use decreased in patients continuing tofacitinib versus those discontinuing tofacitinib (29.7% vs 59.5%, respectively). Reductions in all-cause and UC-related outpatient visits were observed for bio-naïve (- 1.34 and - 0.88, respectively) and bio-experienced (- 4.72 and - 5.16, respectively) patients, post-index. Decreased UC-related costs per year were observed for bio-experienced patients (difference in post-index vs pre-index, - US$12,448; driven by changes in pharmacy costs), but not for bio-naïve patients (US$47,152).
CONCLUSIONS
In this real-world analysis in a mostly bio-experienced population, the majority of US patients with UC initiating tofacitinib remained on therapy at 12 months, and OCS use was reduced with tofacitinib treatment. HCRU (all patients) and UC-related costs were reduced in bio-experienced patients. The majority of patients with ulcerative colitis starting tofacitinib in this real-world study continued therapy at 12 months; there was a reduction in the use of steroids, and a decrease in healthcare resournce utilization and costs.
Identifiants
pubmed: 37639057
doi: 10.1007/s10620-023-08063-4
pii: 10.1007/s10620-023-08063-4
pmc: PMC10516786
doi:
Substances chimiques
Janus Kinase Inhibitors
0
tofacitinib
87LA6FU830
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3985-3993Informations de copyright
© 2023. The Author(s).
Références
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel J-F. Ulcerative colitis. Lancet. 2017;389:1756–1770.
doi: 10.1016/S0140-6736(16)32126-2
pubmed: 27914657
Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV Jr. Incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol. 2017;15:857–863.
doi: 10.1016/j.cgh.2016.10.039
pubmed: 27856364
Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31:693–707.
doi: 10.1111/j.1365-2036.2010.04234.x
pubmed: 20064142
Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384–413.
doi: 10.14309/ajg.0000000000000152
pubmed: 30840605
Brady JE, Stott-Miller M, Mu G, Perera S. Treatment patterns and sequencing in patients with inflammatory bowel disease. Clin Ther. 2018;40:1509-1521.e5.
doi: 10.1016/j.clinthera.2018.07.013
pubmed: 30126706
Sandborn WJ, Ghosh S, Panes J et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616–624.
doi: 10.1056/NEJMoa1112168
pubmed: 22894574
Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.
doi: 10.1056/NEJMoa1606910
pubmed: 28467869
Sandborn WJ, Lawendy N, Danese S et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 70 years of treatment. Aliment Pharmacol Ther. 2022;55:464–478.
doi: 10.1111/apt.16712
pubmed: 34854095
Vermeire S, Su C, Lawendy N et al. Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised RIVETING trial. J Crohns Colitis. 2021;15:1130–1141.
doi: 10.1093/ecco-jcc/jjaa249
pubmed: 33290538
US Food and Drug Administration. Xeljanz® (tofacitinib): highlights of prescribing information, 2021. Available at: https://labeling.pfizer.com/showlabeling.aspx?id=959 . Accessed January 13, 2023.
Weisshof R, Aharoni Golan M, Sossenheimer PH et al. Real-world experience with tofacitinib in IBD at a tertiary center. Dig Dis Sci 2019;64:1945–1951.
doi: 10.1007/s10620-019-05492-y
pubmed: 30734234
pmcid: 6935176
Chaparro M, Garre A, Mesonero F et al. Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry. J Crohns Colitis. 2021;15:35–42.
doi: 10.1093/ecco-jcc/jjaa145
pubmed: 32969471
Lair-Mehiri L, Stefanescu C, Vaysse T et al. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Dig Liver Dis. 2020;52:268–273.
doi: 10.1016/j.dld.2019.10.003
pubmed: 31732444
Lucaciu LA, Constantine-Cooke N, Plevris N et al. Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2021;14:17562848211064004.
doi: 10.1177/17562848211064004
pubmed: 34987608
pmcid: 8721385
Macaluso FS, Maida M, Ventimiglia M, Orlando A. Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies. Dig Liver Dis. 2022;54:183–191.
doi: 10.1016/j.dld.2021.04.018
pubmed: 34011482
Cohen NA, Steinberg JM, Silfen A, et al. Endo-histologic normalization is achievable with tofacitinib and is associated with improved clinical outcomes. Dig Dis Sci. 2022, In Press. https://doi.org/10.1007/s10620-022-07716-0 .
Dalal RS, Mitri J, Goodrick H, Allegretti JR. Real-world comparison of tofacitinib vs ustekinumab among bio-exposed patients with ulcerative colitis: a propensity score analysis. Inflamm Bowel Dis. 2021;27:1694–1697.
doi: 10.1093/ibd/izab097
pubmed: 33988235
pmcid: 8522788
Kulaylat AS, Schaefer EW, Messaris E, Hollenbeak CS. Truven Health Analytics MarketScan databases for clinical research in colon and rectal surgery. Clin Colon Rectal Surg. 2019;32:54–60.
doi: 10.1055/s-0038-1673354
pubmed: 30647546
pmcid: 6327721
IBM Watson Health. IBM MarketScan Research Databases for life sciences researchers, 2019. Available at: https://www.ibm.com/downloads/cas/OWZWJ0QO . Accessed January 13, 2023.
Cohen SB, Haraoui B, Curtis JR et al. Impact of methotrexate discontinuation, interruption, or persistence in US patients with rheumatoid arthritis initiating tofacitinib + oral methotrexate combination. Clin Ther. 2022;44:982-997.e2.
doi: 10.1016/j.clinthera.2022.05.002
pubmed: 35667900
Hudesman DP, Chakravarty SD, Emond B et al. Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study. BMC Rheumatol. 2020;4:16.
doi: 10.1186/s41927-020-0115-2
pubmed: 32266326
pmcid: 7114816
Chiorean MV, Allegretti JR, Sharma PP et al. Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis. BMC Gastroenterol. 2022;22:177.
doi: 10.1186/s12876-022-02215-y
pubmed: 35397501
pmcid: 8994921
Honap S, Chee D, Chapman TP et al. Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience. J Crohns Colitis. 2020;14:1385–1393.
doi: 10.1093/ecco-jcc/jjaa075
pubmed: 32280965
Biemans VBC, Sleutjes JAM, de Vries AC et al. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Aliment Pharmacol Ther. 2020;51:880–888.
doi: 10.1111/apt.15689
pubmed: 32237087
pmcid: 7187329
Perera S, Yang S, Stott-Miller M, Brady J. Analysis of healthcare resource utilization and costs after the initiation of biologic treatment in patients with ulcerative colitis and Crohn’s disease. J Health Econ Outcomes Res. 2018;6:96–112.
doi: 10.36469/9791
pubmed: 32685575
pmcid: 7309948
Curtis JR, Regueiro M, Yun H et al. Tofacitinib treatment safety in moderate to severe ulcerative colitis: comparison of observational population cohort data from the IBM MarketScan® administrative claims database with tofacitinib trial data. Inflamm Bowel Dis. 2021;27:1394–1408.
doi: 10.1093/ibd/izaa289
pubmed: 33324993